Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,346 result(s) found for: Lymphoma. Displaying page 2 of 68.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-002273-24 Sponsor Protocol Number: 81/2004/U Start Date*: 2004-07-20
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A phase 2 trial of CHOP chemotherapy followed by Zevalin for untreated elderly diffuse large b-cell lymphoma DLBCL patients
    Medical condition: Confirmed histologic diagnosis according to the REAL classification of diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012818 PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004442-14 Sponsor Protocol Number: PEG UD0405 Start Date*: 2005-12-06
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI UDINE
    Full Title: A pilot clinical trial to evaluate the ability of pegylate r-metHg-CSF (Pegilgrastim) to accelerate haematology recovery of patients with Non-Hodgkins Lymphoma after High-dose chemiotherapy and aut...
    Medical condition: Patients with - risk Non-Hodgkin's Lymphoma in complete or partial response who underwent autologous PBPC transplantation after high-dose chemiotherapy.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012819 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003729-18 Sponsor Protocol Number: LENALIDOMIDEand DLBCL Start Date*: 2008-09-25
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: A phase II trial to evaluate the safety and activity of single-agent lenalidomide given as maintenance therapy after response to second-line therapy in patients with relapsed diffuse large B cell l...
    Medical condition: patients affected by diffused linfoma with big cells
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002339-44 Sponsor Protocol Number: IGM-2323-001 Start Date*: Information not available in EudraCT
    Sponsor Name:IGM Biosciences, Inc.
    Full Title: A Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
    Medical condition: Relapsed/Refractory (R/R) Non-Hodgkin lymphomas (NHL)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002251-26 Sponsor Protocol Number: CL1-078454-018 Start Date*: 2014-09-08
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies – Extension study
    Medical condition: Hodgkin's Disease (HD) , Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008993 Chronic lymphoid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000743-29 Sponsor Protocol Number: 2142002 Start Date*: 2009-07-02
    Sponsor Name:Heads Study Group
    Full Title: Treatment of patients with post-transplant lymphoproliferative disorder (PILD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy (including first, ...
    Medical condition: Post-tranplant lymphoproliferative disorder (PTLD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003202-14 Sponsor Protocol Number: PCYC-1141-CA Start Date*: 2017-04-12
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination wit...
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029473 Nodular (follicular) lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) CZ (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004970-24 Sponsor Protocol Number: NHL-14 Start Date*: 2008-01-17
    Sponsor Name:AGMT - Arbeitsgemeinschaft Medikamentöse Tumortherapie Gemeinnützige GmbH
    Full Title: Multizentrische Studie über die Cardiotoxizität von R-CHOP (Rituximab, Cyclophosphamid, Doxorubicin, Vincristin und Prednisolon) v. R-COMP (Rituximab, Cyclophosphamid, liposomalem Doxorubicin, Vinc...
    Medical condition: Diffus großzelliges B-Zell Lymphom
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003621-28 Sponsor Protocol Number: CA209-139 Start Date*: 2014-02-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT...
    Medical condition: Lymphoma. Non-Hodgkin
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) SE (Completed) ES (Completed) IT (Completed) DE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001058-16 Sponsor Protocol Number: NLG-LBC-07 Start Date*: 2017-02-15
    Sponsor Name:Nordic Lymphoma Group
    Full Title: A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma.
    Medical condition: Relapsed/refractory diffuse large B-cell lymphoma, including transformed low grade lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003749-40 Sponsor Protocol Number: GO27878 Start Date*: 2014-07-07
    Sponsor Name:F. Hoffmann- La Roche Ltd.
    Full Title: A Phase Ib/II, open label study evaluating the safety and pharmacokinetics of GDC-0199 (ABT-199) in combination with Rituximab (R) or Obinutuzumab (G) plus cyclophosphamide, doxorubicin, vincristin...
    Medical condition: B-cell non-hodgkin's lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029601 Non-Hodgkin's lymphoma refractory PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) HU (Completed) CZ (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005299-26 Sponsor Protocol Number: 54767414LYM2001 Start Date*: 2015-06-08
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
    Medical condition: Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    18.0 100000004851 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    18.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-006398-41 Sponsor Protocol Number: E7438-M081-501 Start Date*: 2022-01-27
    Sponsor Name:Eisai Co., Ltd.
    Full Title: A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan
    Medical condition: Lymphoma, Follicular
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085128 Follicular lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-002241-22 Sponsor Protocol Number: CA186-107 Start Date*: 2014-12-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodg...
    Medical condition: Advanced Solid Tumors Advanced B-cell NHL
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10065252 Solid tumor LLT
    17.1 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005506-42 Sponsor Protocol Number: NHL-HIV+ Start Date*: 2007-10-19
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) IN HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT
    Medical condition: HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    10029547 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005459-13 Sponsor Protocol Number: IPI-145-19 Start Date*: 2015-09-15
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) ES (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003987-74 Sponsor Protocol Number: 114-NH-302 Start Date*: 2007-06-08
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination with Rituximab for Subjects with Relapsed, Follicular Non-Hodgkin’s Lymphoma who Previously Responded...
    Medical condition: Relapsed, Follicular Non-Hodgkin’s Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) GB (Prematurely Ended) SK (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000124-15 Sponsor Protocol Number: TAS-2010 Start Date*: 2011-06-22
    Sponsor Name:Ergomed Clinical Research Limited
    Full Title: An Open-Label, Multi-Center Phase I/IIa Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Relapsed/Refractory Aggressive Non-...
    Medical condition: aggressive non-Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002272-27 Sponsor Protocol Number: DSHNHL2015-1 Start Date*: 2017-04-06
    Sponsor Name:Saarland University
    Full Title: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabin...
    Medical condition: Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) NL (Ongoing) PL (Completed) AT (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003821-25 Sponsor Protocol Number: CHUBX 2007/11 Start Date*: 2007-10-05
    Sponsor Name:CHU de Bordeaux
    Full Title: Etude de la tolérance et de l'efficacité du Zevalin dans un conditionnement à intensité réduite avant allogreffe de cellules souches hématopoïétiques dans les lymphomes B CD20+ agressifs de l'adult...
    Medical condition: L’association du Zevalin®, anticorps monoclonal anti-CD20 radio marqué, à une chimiothérapie immunosuppressive permettrait d’accroître l’efficacité d’un conditionnement à intensité réduite à base d...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012820 Diffuse large B-cell lymphoma NOS LLT
    9.1 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 19:21:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA